According to a report by IntelMarketResearch, the global Nuclear Imaging Devices Market was valued at USD 1.60 billion in 2025 and is estimated to reach USD 1.68 billion in 2026 before expanding to USD 2.45 billion by 2034, registering a CAGR of 4.8% during 2025–2034. The market is being shaped by increasing cancer incidence, rising cardiovascular and neurological disease burden, rapid development of hybrid imaging systems, AI-enhanced image reconstruction, expansion of theranostic applications and advances in radiopharmaceutical infrastructure.

Nuclear imaging devices include PET, SPECT and hybrid systems such as PET/CT, PET/MRI and SPECT/CT. These technologies combine radiotracer-based functional information with anatomical imaging to support applications across oncology, cardiology, neurology, orthopedics and other clinical areas.

Explore the full report: Nuclear Imaging Devices Market Report

Why Is Demand Increasing?

• Growing cancer burden: Rising cancer incidence is increasing demand for PET and SPECT imaging in diagnosis, staging, treatment planning and response monitoring.

• Expansion of hybrid imaging: PET/CT and PET/MRI combine functional and anatomical information, improving the clinical utility of nuclear imaging.

• AI-enhanced reconstruction: Artificial intelligence is being integrated into image reconstruction, lesion detection and quantitative analysis.

• Growth of theranostics: Diagnostic radiotracers linked with therapeutic radionuclides are creating new applications for nuclear imaging in personalized treatment pathways.

• Radiopharmaceutical innovation: Development of new tracers and localized isotope-production capabilities is expanding the clinical applications of nuclear imaging.

Medical Imaging Technology Watch

The nuclear imaging industry is increasingly moving toward hybrid, digital and AI-enabled systems. PET/CT remains an important platform because it combines molecular information with anatomical localization, while PET/MRI is gaining relevance in applications where soft-tissue contrast is particularly important.

AI-enhanced image reconstruction is another major technology direction. Deep-learning algorithms can assist with image reconstruction, lesion segmentation, noise reduction and quantitative standardization. These capabilities can support faster workflows and help imaging centers manage patient throughput.

Theranostics is also changing the role of nuclear imaging. Diagnostic PET scans can be used to identify and characterize patients for radioligand therapies, creating an integrated diagnostic-treatment pathway. The growing pipeline of radiopharmaceuticals for oncology and other diseases is therefore creating additional demand for high-resolution nuclear imaging systems.

Compact cyclotrons and localized radiopharmaceutical production are also being explored as ways to reduce dependence on complex isotope transportation networks, particularly for short-half-life tracers.

Download the free sample report: Download Free Sample Report

Why This Market Matters

The Nuclear Imaging Devices Market is becoming increasingly important as healthcare systems seek more precise approaches to cancer diagnosis, treatment monitoring and personalized medicine. Hybrid imaging systems can provide both functional and anatomical information, while AI-enabled workflows are helping improve image processing and operational efficiency.

Theranostic applications are creating an additional connection between diagnostic imaging and targeted radiopharmaceutical therapy. As new diagnostic and therapeutic radiopharmaceuticals enter clinical development and commercialization, demand for imaging systems capable of identifying and quantifying specific molecular targets is expected to remain an important market theme.

At the same time, high equipment costs, infrastructure requirements, radiopharmaceutical logistics, regulatory complexity and shortages of specialized nuclear-medicine personnel can constrain adoption. These factors are particularly important for midsized hospitals and emerging healthcare markets.

Competitive Landscape

• Siemens Healthineers — Participates across PET/CT, PET/MRI and SPECT technologies, with emphasis on digital detector technologies and advanced imaging workflows.

• GE Healthineers — Provides nuclear imaging platforms and is expanding capabilities related to theranostics and imaging-agent integration.

• Philips Healthcare — Participates in nuclear imaging with digital imaging and AI-supported reconstruction capabilities.

• Canon Medical Systems — Competes in hybrid imaging and is expanding AI-related imaging capabilities.

• Hitachi Healthcare — Participates in hybrid PET/CT systems and time-of-flight technology.

• United Imaging Healthcare — Targets the Asia-Pacific market with cost-optimized advanced imaging platforms.

• Neusoft Medical Systems — Participates with compact SPECT systems and imaging solutions.

• Mediso — Addresses specialized and regional nuclear imaging applications.

• Fujifilm Healthcare, Varian Medical Systems and Mindray — Represent additional companies covered in the competitive landscape.

View the full report: Full Nuclear Imaging Devices Market Report

FAQ

Q: What is the Nuclear Imaging Devices Market size?
A: The global market was valued at USD 1.60 billion in 2025 and is projected to reach USD 2.45 billion by 2034 at a CAGR of 4.8%.

Q: Which region leads the market?
A: North America is identified as the largest regional market in 2025.

Q: What are the major growth drivers?
A: Major growth factors include rising cancer and chronic-disease burden, adoption of hybrid imaging systems, AI-enhanced image reconstruction, radiopharmaceutical innovation and expansion of theranostic applications.

What Does the Full Report Cover?

The complete study provides a detailed examination of the global Nuclear Imaging Devices Market across the 2026–2034 forecast period. It covers market size, historical and forecast performance, product segmentation, application analysis, end-user analysis, technology developments and deployment models.

The report evaluates PET, SPECT, hybrid PET/CT and PET/MRI systems, along with oncology, cardiology, neurology and other applications. It also provides regional and country-level analysis across North America, Europe, Asia-Pacific, South America and the Middle East & Africa.

Additional coverage includes competitive positioning, company profiles, product offerings, AI-driven image reconstruction, digital detector technologies, compact cyclotrons, cloud-based analytics, theranostics, radiopharmaceutical development, reimbursement, regulatory considerations, market drivers, restraints and opportunities.

View the complete report: Nuclear Imaging Devices Full Report

Download the free sample: Nuclear Imaging Devices Sample

Related Reports

• Central Nervous System Stimulant Drugs Market — CNS Stimulant Drugs Market

• Livestock Management App Market — Livestock Management App Market

• Digital Pathology AI-Assisted Diagnostic System Market — Digital Pathology AI-Assisted Diagnostic System Market

About IntelMarketResearch

IntelMarketResearch provides market intelligence, industry analysis, competitive research, forecasting and customized research support across global markets, serving manufacturers, suppliers, investors, regulators and other industry stakeholders.

Contact Details

Website: www.intelmarketresearch.com
Asia-Pacific: +91 9169164321
Email: help@intelmarketresearch.com